| This week's sponsor is Premier Research. | | | Beating the Odds in Early-Phase Oncology Trials
Despite advances in molecular targeting, developing new cancer drugs remains a long shot. Read our white paper for insights on maximizing early-phase trial success. Premier Research. It's what we do. Best. |
Today's Rundown Allergan CGRP drug hits goals in phase 3 migraine trial Array’s encorafenib/binimetinib beats Roche’s Zelboraf in phase 3 Chinese upstart DL Medicine forges alliance with Pfizer [Sponsored] Can emerging technology help biopharma improve the returns on R&D? Chinese funds plow cash into British VC shops After a round trip, ex-Intellia CEO Bermingham lands back at Atlas Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson & Johnson Featured Story | | | Tuesday, February 6, 2018 A phase 3 trial of Allergan’s oral CGRP drug ubrogepant has met its co-primary endpoints. The drug offered greater relief than placebo to acute migraine patients in the two hours after dosing, but the size of the effect and cases of elevated liver enzymes leave room for doubt about its prospects. |
|
|
| This week's sponsor is Dell EMC. | | | [Webinar] Is Your Life Science Data "F-A-I-R"?
Tuesday, February 13 | 2pm ET / 11am PT
Is Your Life Science Data "F-A-I-R"? Join DataFrameworks & Dell EMC in this webinar to discover a new approach to create scientific data that is findable, accessible, interoperable, and reusable. Register now! |
Top Stories Tuesday, February 6, 2018 Array's combo treatment nearly doubled survival in patients with BRAF-mutant melanoma compared to Roche’s Zelboraf. Tuesday, February 6, 2018 Chinese biotech NetVation DL Medicine has arrived on the scene with a two-year alliance with Pfizer, plus an equity investment from the big pharma group. Monday, February 5, 2018 While biopharma companies are investing more than ever to develop innovative therapies, returns are not keeping pace. How can emerging technologies help improve productivity? Learn more from Deloitte’s annual ROI analysis. Tuesday, February 6, 2018 Chinese investors are set to pump money into two British funds. The agreements stand to create investment vehicles with more than $1 billion (€810 million) under management and an interest in bringing British innovations to China. Tuesday, February 6, 2018 A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where. Today we found out, and there is little surprise on this occasion as Bermingham has returned full circle, back at Atlas Ventures, the firm that also helped launch Intellia. Tuesday, February 6, 2018 Pfizer, Astellas and J&J envision a wide-open new field for patients whose prostate cancer hasn't yet spread, and they've got data that could open the gates. Next up: a high-stakes market scrum pitting Pfizer and Astellas' Xtandi against J&J's candidate apalutamide—and, potentially and crucially, generics of J&J's blockbuster Zytiga. | This week's sponsor is IQVIA. | | | Discover a new path to your success via Human Data Science. IMS Health and Quintiles are now IQVIA™ – created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. Join the journey today. Learn More. |
Resources Sponsored by: RBC Wealth Management Guiding corporate executives through regulatory complexities, while delivering an array of sophisticated investment options. Learn more. Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Watch this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Sponsored by: Veeva Systems Expanding into new markets places a spotlight on inefficient processes. Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA | 